Inhibition of CD38 and supplementation of nicotinamide riboside ameliorate lipopolysaccharide-induced microglial and astrocytic neuroinflammation by increasing NAD()

Plain-language summary

Published 2021 in J Neurochem, this work by Roboon J and collaborators tackles a specific question within science-focused NMN/NAD+ research.

Key findings reported by the authors

• Preclinical animal study in J Neurochem (2021) investigating NAD+/NMN pathway mechanisms
• Findings inform translational rationale; not yet replicated in humans
• Mechanistic data on tissue-specific NAD+ effects

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to science decisions, with secondary relevance to compare. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.